{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:49:30Z","timestamp":1792705770839,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40120-022-00400-5","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T16:02:40Z","timestamp":1662220960000},"page":"1705-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-657X","authenticated-orcid":false,"given":"Michael C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence G.","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"issue":"2","key":"400_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/157015909788848884","volume":"7","author":"WR Garnett","year":"2009","unstructured":"Garnett WR, St Louis EK, Henry TR, Bramley T. Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr Neuropharmacol. 2009;7(2):83\u201395.","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"400_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473\u201381.","journal-title":"Lancet Neurol"},{"issue":"2","key":"400_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/157015909788848929","volume":"7","author":"EK St Louis","year":"2009","unstructured":"St Louis EK. Truly \u201crational\u201d polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol. 2009;7(2):96\u2013105.","journal-title":"Curr Neuropharmacol"},{"key":"400_CR4","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]. Paramus: SK Life Science, Inc.; 2022."},{"issue":"22","key":"400_CR5","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase\u00a02 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"issue":"1","key":"400_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348.","journal-title":"Lancet Neurol"},{"issue":"6","key":"400_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase\u00a03, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"issue":"11","key":"400_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34(11):1105\u201320.","journal-title":"CNS Drugs"},{"issue":"1","key":"400_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/ane.13422","volume":"144","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang J, Wang C. Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: a meta-analysis. Acta Neurol Scand. 2021;144(1):58\u201366.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"400_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40265-019-01250-6","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Cenobamate: first approval. Drugs. 2020;80(1):73\u20138.","journal-title":"Drugs"},{"issue":"3","key":"400_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/epi.16832","volume":"62","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62(3):596\u2013614.","journal-title":"Epilepsia"},{"key":"400_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"855","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin HS, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175\u201382.","journal-title":"Eur J Pharmacol"},{"key":"400_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117","volume":"879","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879: 173117.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"400_CR14","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61(11):2329\u201339.","journal-title":"Epilepsia"},{"issue":"3","key":"400_CR15","first-page":"741","volume":"232","author":"SG Piredda","year":"1985","unstructured":"Piredda SG, Woodhead JH, Swinyard EA. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J Pharmacol Exp Ther. 1985;232(3):741\u20135.","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl 1","key":"400_CR16","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1528-1157.1997.tb04523.x","volume":"38","author":"HS White","year":"1997","unstructured":"White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 1997;38(suppl 1):S9\u201317.","journal-title":"Epilepsia"},{"issue":"8","key":"400_CR17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/epi.12657","volume":"55","author":"LL Anderson","year":"2014","unstructured":"Anderson LL, Thompson CH, Hawkins NA, et al. Antiepileptic activity of preferential inhibitors of persistent sodium current. Epilepsia. 2014;55(8):1274\u201383.","journal-title":"Epilepsia"},{"issue":"1","key":"400_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1535-7511.2007.00156.x","volume":"7","author":"CE Stafstrom","year":"2007","unstructured":"Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr. 2007;7(1):15\u201322.","journal-title":"Epilepsy Curr"},{"issue":"10","key":"400_CR19","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1111\/j.1460-9568.2004.03400.x","volume":"19","author":"M Vreugdenhil","year":"2004","unstructured":"Vreugdenhil M, Hoogland G, van Veelen CW, Wadman WJ. Persistent sodium current in subicular neurons isolated from patients with temporal lobe epilepsy. Eur J Neurosci. 2004;19(10):2769\u201378.","journal-title":"Eur J Neurosci"},{"issue":"6","key":"400_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609\u201318.","journal-title":"CNS Drugs"},{"issue":"12","key":"400_CR21","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Abou-Khalil B, Aboumatar S, et al. Post-hoc analysis of a phase\u00a03, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016\u201328.","journal-title":"Epilepsia"},{"issue":"8","key":"400_CR22","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/epi.16610","volume":"61","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E. A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia. 2020;61(8):1668\u201377.","journal-title":"Epilepsia"},{"key":"400_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108341","volume":"124","author":"L Nobili","year":"2021","unstructured":"Nobili L, Beniczky S, Eriksson SH, et al. Expert opinion: managing sleep disturbances in people with epilepsy. Epilepsy Behav. 2021;124: 108341.","journal-title":"Epilepsy Behav"},{"key":"400_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.seizure.2020.08.015","volume":"81","author":"E Kaufmann","year":"2020","unstructured":"Kaufmann E, Bartolomei F, Boon P, et al. European expert opinion on ANT-DBS therapy for patients with drug-resistant epilepsy (a Delphi consensus). Seizure. 2020;81:201\u20139.","journal-title":"Seizure"},{"issue":"4","key":"400_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/cpdd.769","volume":"9","author":"L Vernillet","year":"2020","unstructured":"Vernillet L, Greene SA, Kamin M. Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev. 2020;9(4):428\u201343.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"suppl S1","key":"400_CR26","first-page":"S91","volume":"103","author":"L Vernillet","year":"2018","unstructured":"Vernillet L, Kamin M. Drug\u2013drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium [abstract]. Clin Pharmacol Ther. 2018;103(suppl S1):S91.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"400_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1684\/epd.2014.0714","volume":"16","author":"G Zaccara","year":"2014","unstructured":"Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409\u201331.","journal-title":"Epileptic Disord"},{"issue":"8","key":"400_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia"},{"issue":"4","key":"400_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608\u201311.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"400_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cts.13204","volume":"15","author":"SA Greene","year":"2021","unstructured":"Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2021;15(4):899\u2013911.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"400_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86\u201395.","journal-title":"Drug Metab Rev"},{"issue":"2","key":"400_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/epi.13973","volume":"59","author":"MJ Brodie","year":"2018","unstructured":"Brodie MJ, Ben-Menachem E. Cannabinoids for epilepsy: what do we know and where do we go? Epilepsia. 2018;59(2):291\u20136.","journal-title":"Epilepsia"},{"key":"400_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106459","volume":"99","author":"P Klein","year":"2019","unstructured":"Klein P, Tolbert D, Gidal BE. Drug\u2013drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy Behav. 2019;99: 106459.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"400_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamaneurol.2020.0032","volume":"77","author":"BAA Alsfouk","year":"2020","unstructured":"Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurol. 2020;77(5):574\u201381.","journal-title":"JAMA Neurol"},{"issue":"1","key":"400_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1212\/WNL.62.1.23","volume":"62","author":"FG Gilliam","year":"2004","unstructured":"Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62(1):23\u20137.","journal-title":"Neurology"},{"issue":"12","key":"400_CR36","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1528-1167.2011.03325.x","volume":"52","author":"C Luoni","year":"2011","unstructured":"Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52(12):2181\u201391.","journal-title":"Epilepsia"},{"issue":"10282","key":"400_CR37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","volume":"397","author":"A Marson","year":"2021","unstructured":"Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363\u201374.","journal-title":"Lancet"},{"issue":"3","key":"400_CR38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2006","unstructured":"Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246\u201355.","journal-title":"Br J Clin Pharmacol"},{"key":"400_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.seizure.2015.02.025","volume":"27","author":"D Dash","year":"2015","unstructured":"Dash D, Aggarwal V, Joshi R, Padma MV, Tripathi M. Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy. Seizure. 2015;27:25\u20139.","journal-title":"Seizure"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00400-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T12:01:47Z","timestamp":1674129707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00400-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00400-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed video abstract and infographic were retrospectively added to this publication.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}